ReviewJournal of personalized medicine2022
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.International journal of molecular sciences · 2024Pooled it
- Hierarchical modeling of tumor subtypes in cell lines using large-scale genomic datasets.iScience · 2026Article
- Development of an Integrated Radiotherapy Simulation Platform with AI-Driven Segmentation and Ray-Casting-Based Dosimetric Evaluation.Bioengineering (Basel, Switzerland) · 2026Article
- Resistance Mechanisms in Immunotherapy-Radiotherapy/Chemotherapy Combinations in Locally Advanced Head & Neck Squamous Cell Carcinoma.Oncology research · 2026Review
- Liquid Biopsy's Role in Head and Neck Tumors: Changing Paradigms in the Era of Precision Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- Head and neck tumor organoid grown under simplified media conditions model tumor biology and chemoradiation responses.Scientific reports · 2025Article
- Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies.Heliyon · 2025Review
- Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma.Frontiers in oncology · 2025Review
- Amifostine and Melatonin Prevent Acute Salivary Gland Dysfunction 10 Days After Radiation Through Anti-Ferroptosis and Anti-Ferritinophagy Effects.International journal of molecular sciences · 2024Article
- Review
- The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma.Biomedicines · 2024Review
- Article
- Anti-Tumor Potential of Post-Translational Modifications of PD-1.Current issues in molecular biology · 2024Review
- Review
- Molecular pathways and targeted therapies in head and neck cancers pathogenesis.Frontiers in oncology · 2024Review
- Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy.Frontiers in oncology · 2024Article
- The role of cGAS-STING signaling in the development and therapy of head and neck squamous cell carcinoma.Frontiers in immunology · 2024Review
- Outcomes Following Autologous Fat Grafting in Patients with Sequelae of Head and Neck Cancer Treatment.Cancers · 2023Article
- Global cluster analysis and network visualization in organoids in cancer research: a scientometric mapping from 1991 to 2021.Frontiers in oncology · 2023Article
- EMT and Tumor Turning Point Analysis in 3D Spheroid Culture of HNSCC and Mesenchymal Stem Cells.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck cancers (HNCs) represent the sixth most widespread malignancy worldwide. Surgery, radiotherapy, chemotherapeutic and immunotherapeutic drugs represent the main clinical approaches for HNC patients. Moreover, HNCs are characterised by an elevated mutational load; however, specific genetic mutations or biomarkers have not yet been found. In this scenario, personalised medicine is showing its efficacy. To study the reliability and the effects of personalised treatments, preclinical research can take advantage of next-generation sequencing and innovative technologies that have been developed to obtain genomic and multi-omic profiles to drive personalised treatments. The crosstalk between malignant and healthy components, as well as interactions with extracellular matrices, are important features which are responsible for treatment failure. Preclinical research has constantly implemented in vitro and in vivo models to mimic the natural tumour microenvironment. Among them, 3D systems have been developed to reproduce the tumour mass architecture, such as biomimetic scaffolds and organoids. In addition, in vivo models have been changed over the last decades to overcome problems such as animal management complexity and time-consuming experiments. In this review, we will explore the new approaches aimed to improve preclinical tools to study and apply precision medicine as a therapeutic option for patients affected by HNCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.